The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application
Open accessAbstract
NKP-1339 is the first-in-class ruthenium-based anticancer drug in clinical development against solid cancer and has recently been studied successfully in a phase I clinical trial. Ruthenium compounds such as KP1019 (indazolium trans-[tetrachloridobis(1H-indazole)ruthenate(III)]) and NKP-1339 (the sodium salt analogue of KP1019, sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)]) have a high tumour targeting potential based (1) on their strong binding to serum proteins such as albumin and transferrin as well as (2) on their activation in the reductive tumour milieu. The redox activity of ruthenium compounds is believed to represent one major mode of action leading to disturbance of the cellular redox balance and, consequently, induction of G2/M cell cycle arrest, blockage of DNA synthesis, and induction of apoptosis via the mitochondrial pathway. Moreover, potent synergistic activities of NKP-1339 with the clinically approved tyrosine kinase inhibitor sorafenib were recently reported in vitro and in vivo. Taken together, KP1019 and NKP-1339 are promising drug candidates, and especially the very limited side effects observed so far in clinical phase I trials seem to be a major advantage of this class of ruthenium drugs as compared to other chemotherapeutics and targeted anticancer compounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Free radicals in biology and medicine
(1991) · General Pharmacology: The Vascular System · doi:10.1016/0306-3623(91)90478-o · Cited by 17,178
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Schafer, F. Q., & Buettner, G. R. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(01)00480-4 · Cited by 4,587
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Kratz, F. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.010 · Cited by 2,151
Free Radicals in Biology and Medicine
Kovacic, P. (1986) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600750133 · Cited by 982
Non-Platinum Chemotherapeutic Metallopharmaceuticals
Clarke, M. J., Zhu, F., & Frasca, D. R. (1999) · Chemical Reviews · doi:10.1021/cr9804238 · Cited by 908
Rademaker-Lakhai, J. M., van den Bongard, D., Pluim, D., Beijnen, J. H., & Schellens, J. H. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0746 · Cited by 833
Hartinger, C. G., Jakupec, M. A., Zorbas‐Seifried, S., Groessl, M., Egger, A., Berger, W., Zorbas, H., Dyson, P. J., & Keppler, B. K. (2008) · Chemistry & Biodiversity · doi:10.1002/cbdv.200890195 · Cited by 830
Self-citationFormation and transfer of disulphide bonds in living cells
Sevier, C. S., & Kaiser, C. A. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm954 · Cited by 796
Ruthenium metallopharmaceuticals
Clarke, M. J. (2003) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(02)00312-0 · Cited by 687
Anticancer Activity of Metal Complexes: Involvement of Redox Processes
Jungwirth, U., Kowol, C. R., Keppler, B. K., Hartinger, C. G., Berger, W., & Heffeter, P. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3663 · Cited by 554
Self-citationNi, M., Zhang, Y., & Lee, A. S. (2011) · Biochemical Journal · doi:10.1042/bj20101569 · Cited by 530
Approaching tumour therapy beyond platinum drugs
Bergamo, A., Gaiddon, C., Schellens, J. H. M., Beijnen, J. H., & Sava, G. (2012) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2011.09.030 · Cited by 514
Resistance against novel anticancer metal compounds: Differences and similarities
Heffeter, P., Jungwirth, U., Jakupec, M., Hartinger, C., Galanski, M. S., Elbling, L., Micksche, M., Keppler, B., & Berger, W. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2008.02.002 · Cited by 242
Self-citationLentz, F., Drescher, A., Lindauer, A., Henke, M., Hilger, R. A., Hartinger, C. G., Scheulen, M. E., Dittrich, C., Keppler, B. K., & Jaehde, U. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328322fbc5 · Cited by 239
Self-citationPongratz, M., Schluga, P., Jakupec, M. A., Arion, V. B., Hartinger, C. G., Allmaier, G., & Keppler, B. K. (2004) · Journal of Analytical Atomic Spectrometry · doi:10.1039/b309160k · Cited by 206
Self-citationThe binding properties of two antitumor ruthenium(III) complexes to apotransferrin.
Kratz, F., Hartmann, M., Keppler, B., & Messori, L. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)41984-3 · Cited by 204
Self-citationHeterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells
Kapitza, S., Pongratz, M., Jakupec, M. A., Heffeter, P., Berger, W., Lackinger, L., Keppler, B. K., & Marian, B. (2005) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0617-0 · Cited by 200
Self-citationElectron-transfer activated metal-based anticancer drugs
Reisner, E., Arion, V. B., Keppler, B. K., & Pombeiro, A. J. L. (2008) · Inorganica Chimica Acta · doi:10.1016/j.ica.2006.12.005 · Cited by 197
Self-citationIntracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339
Heffeter, P., Böck, K., Atil, B., Reza Hoda, M. A., Körner, W., Bartel, C., Jungwirth, U., Keppler, B. K., Micksche, M., Berger, W., et al. (2010) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-010-0642-1 · Cited by 173
Self-citationJakupec, M. A., Reisner, E., Eichinger, A., Pongratz, M., Arion, V. B., Galanski, M. S., Hartinger, C. G., & Keppler, B. K. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0490742 · Cited by 164
Self-citationGroessl, M., Zava, O., & Dyson, P. J. (2011) · Metallomics · doi:10.1039/c0mt00101e · Cited by 161
New Ruthenium Complexes for the Treatment of Cancer
Keppler, B. K., Henn, M., Juhl, U. M., Berger, M. R., Niebl, R., & Wagner, F. E. (1989) · Progress in clinical biochemistry and medicine · doi:10.1007/978-3-642-74760-1_3 · Cited by 143
Self-citationInhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A
Vacca, A., Bruno, M., Boccarelli, A., Coluccia, M., Ribatti, D., Bergamo, A., Garbisa, S., Sartor, L., & Sava, G. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600176 · Cited by 140
Zorzet, S., Bergamo, A., Cocchietto, M., Sorc, A., Gava, B., Alessio, E., Iengo, E., & Sava, G. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38990-6 · Cited by 120
Kapitza, S. B., Jakupec, M. A., Uhl, M., Keppler, B. K., & Marian, B. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.01.002 · Cited by 119
Self-citationGroessl, M., Tsybin, Y. O., Hartinger, C. G., Keppler, B. K., & Dyson, P. J. (2010) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-010-0635-0 · Cited by 106
Self-citationAntiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers
Morbidelli, L., Donnini, S., Filippi, S., Luigi Messori, A., Piccioli, F., Orioli, P., Sava, G., & Ziche, M. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600906 · Cited by 92
The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo
Heffeter, P., Atil, B., Kryeziu, K., Groza, D., Koellensperger, G., Körner, W., Jungwirth, U., Mohr, T. T., Keppler, B. K., & Berger, W. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.05.018 · Cited by 92
Self-citationSava, G., Frausin, F., Cocchietto, M., Vita, F., Podda, E., Spessotto, P., Furlani, A., Scarcia, V., & Zabucchi, G. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.01.034 · Cited by 91
Timerbaev, A. R., Rudnev, A. V., Semenova, O. P., Hartinger, C. G., & Keppler, B. K. (2005) · Analytical Biochemistry · doi:10.1016/j.ab.2005.03.020 · Cited by 84
Self-citationPiccioli, F., Sabatini, S., Luigi Messori, A., Orioli, P., Hartinger, C. G., & Keppler, B. K. (2004) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2004.04.002 · Cited by 83
Self-citationHeffeter, P., Pongratz, M., Steiner, E., Chiba, P., Jakupec, M. A., Elbling, L., Marian, B., Körner, W., Sevelda, F., Micksche, M., et al. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.073395 · Cited by 76
Self-citationBytzek, A. K., Boeck, K., Hermann, G., et al. (2011) · Metallomics · doi:10.1039/c1mt00055a · Cited by 64
Ruthenium and Other Non‐Platinum Anticancer Compounds
Bratsos, I., Gianferrara, T., Alessio, E., Hartinger, C. G., Jakupec, M. A., & Keppler, B. K. (2011) · Wiley eBooks · doi:10.1002/9783527633104.ch5 · Cited by 54
Self-citationHummer, A. A., Heffeter, P., Berger, W., Filipits, M., Batchelor, D. R., Büchel, G. E., Jakupec, M. A., Keppler, B. K., & Rompel, A. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301648f · Cited by 49
Self-citationTimerbaev, A. R., Foteeva, L. S., Rudnev, A. V., Abramski, J. K., Pawlak, K., Hartinger, C. G., Jarosz, M., & Keppler, B. K. (2007) · Electrophoresis · doi:10.1002/elps.200600707 · Cited by 47
Self-citationStevens, S. K., Strehle, A. P., Miller, R. L., et al. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.079657 · Cited by 45
Cytotoxic effects of a doxorubicin-transferrin conjugate in multidrug-resistant KB cells
Fritzer, M., Szekeres, T., Szüts, V., Jarayam, H. N., & Goldenberg, H. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)02225-2 · Cited by 43
Cytotoxicity of a transferrin‐adriamycin conjugate to anthracycline‐resistant cells
Fritzer, M., Barabás, K., Szüts, V., Bérczi, A., Szekeres, T., Faulk, W. P., & Goldenberg, H. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910520421 · Cited by 41
Bencini, A., Failli, P., Valtancoli, B., & Bani, D. (2010) · Cardiovascular & Hematological Agents in Medicinal Chemistry · doi:10.2174/187152510791698389 · Cited by 35
Influence of ascorbic acid on the activity of the investigational anticancer drug KP1019
Bartel, C., Egger, A., Jakupec, M. A., Heffeter, P., Galanski, M. S., Berger, W., & Keppler, B. K. (2011) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-011-0809-4 · Cited by 29
Self-citationPark, Y. S., David, A. E., Huang, Y., Park, J. B., He, H., Byun, Y., & Yang, V. C.-M. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.04.026 · Cited by 29
Brown, S., Georgatos, M., Reifel, C. W., Song, J. H., Shin, S. H., & Hong, M. G. L. (2002) · Endocrine · doi:10.1385/endo:18:1:91 · Cited by 16
Cited by
The medicinal chemistry of ferrocene and its derivatives
Patra, M., & Gasser, G. (2017) · Nature Reviews Chemistry · doi:10.1038/s41570-017-0066 · Cited by 609
Combination of Ru(ii) complexes and light: new frontiers in cancer therapy
Mari, C., Pierroz, V., Ferrari, S., & Gasser, G. (2015) · Chemical Science · doi:10.1039/c4sc03759f · Cited by 570
Hypoxia-targeted drug delivery
Sharma, A., Arambula, J. F., Koo, S., Kumar, R., Singh, H., Sessler, J. L., & Kim, J. S. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00304a · Cited by 542
Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?
Thota, S., Rodrigues, D. A., Crans, D. C., & Barreiro, E. J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01689 · Cited by 476
The development of RAPTA compounds for the treatment of tumors
Murray, B. S., Babak, M. V., Hartinger, C. G., & Dyson, P. J. (2016) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2015.06.014 · Cited by 455
Metadata
- Authors
- Trondl, R., Heffeter, P., Kowol, C. R., Jakupec, M. A., Berger, W., & Keppler, B. K.
- Venue
- Chem. Sci.
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2014-04-04
- Volume
- 5
- Issue
- 8
- Pages
- 2925-2932
- ISSN
- 2041-6520 (ISSN-L)
- 2041-6539
- OpenAlex
- W2112253518
- Cited by
- 675
- References
- 44
- FWCI
- 28.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.